
Colorectal Cancer
Latest News

June 7th 2016
By Darcy Lewis
The combination of cobimetinib (Cotellic) and atezolizumab (Tecentriq) is safe and clinically active in advanced colorectal cancer and resulted in a higher clinical response rate in patients with microsatellite stable (MSS) colorectal cancer patients than either agent alone.
Latest Videos

CME Content
More News

Navesh K. Sharma, DO, PhD, discusses the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in patients with liver metastatic colorectal cancer.

Given the numerous available treatment options, the most important issue in frontline colorectal cancer (CRC) care is clarifying the goals of therapy, according to Wells Messersmith, MD.

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD





























































